Capricor Therapeutics Announces $4 Million Registered Direct Offering

Capricor Therapeutics (NASDAQ:CAPR) has entered into a subscription agreement for a registered direct offering for proceeds of approximately $4.1 million.
As quoted in the press release:

The closing of the offering is expected to take place on or about March 15, 2016, subject to the satisfaction of customary closing conditions.
The offering includes participation from new and existing investors as well as certain officers and directors of Capricor. The net proceeds of the offering will be used primarily for working capital, including ongoing or planned clinical trials, and general corporate purposes.

Click here for the full press release.